ABI has developed a platform for the high accumulation of recombinant proteins with unique advantages over existing technologies. This includes several applications including: 1) Using the platform to commercialized animal-free pharmaceutical reagents and industrial proteins, 2) Developing oral vaccines for both human and animals, 3) Developing a high intensity natural sweetener. The technology is also well suited to produce antibodies and other protein drugs for which proof-of concept has been demonstrated. ABI is now seeking partners to help commercialize products in the latter stages of development as well as initiate collaborations for new products with partners.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Orally deliverred hepatitis vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):